Onco-hematology Molecular Testing Market Size, Share & Trends Analysis Report By Blood Cancer Type, By Technology, By Blood Cancer Biomarker, By End-User, By Region, And By Segment Forecasts, 2023-2031
Segmentation of Onco-hematology Molecular Testing Market-
- Onco-hematology Molecular Testing Market By Blood Cancer Type
- Chronic Myeloid Leukemia
- Polycythemia Vera
- Essential Thrombocythaemia
- Myelofibrosis
- Myeloproliferative Neoplasms
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- Onco-hematology Molecular Testing Market By Technology
- qPCR
- dPCR
- Next-Generation Sequencing
- Others
- Onco-hematology Molecular Testing Market By Blood Cancer Biomarker
- BCR-ABL1 Mbcr
- JAK2
- CALR
- MPL
- PML-RARA
- NPM1
- RUNX1-RUNX1T1
- CBFB-MYH11
- BCR-ABL1 mbcr
- Onco-hematology Molecular Testing Market By End-user
- National Reference Lab / Specialty Lab
- University Hospital / Oncology Center
- Community Hospital / IDN (Regional/National)
Onco-hematology Molecular Testing Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Onco-hematology Molecular Testing Market Snapshot
Chapter 4. Global Onco-hematology Molecular Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Blood Cancer Type Estimates & Trend Analysis
5.1. By Blood Cancer Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Type:
5.2.1. Chronic Myeloid Leukemia
5.2.1.1. Polycythemia Vera
5.2.1.2. Essential Thrombocythemia
5.2.1.3. Myelofibrosis
5.2.2. Myeloproliferative Neoplasms
5.2.3. Acute Myeloid Leukemia
5.2.4. Acute Lymphoblastic Leukemia
Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Blood Cancer Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Technology:
6.2.1. qPCR
6.2.2. dPCR
6.2.3. Next-Generation Sequencing
6.2.4. Others
Chapter 7. Market Segmentation 3: By Blood Cancer Biomarker Estimates & Trend Analysis
7.1. By Blood Cancer Type & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Biomarker:
7.2.1. BCR-ABL1 Mbcr
7.2.2. JAK2
7.2.3. CALR
7.2.4. MPL
7.2.5. PML-RARA
7.2.6. NPM1
7.2.7. RUNX1-RUNX1T1
7.2.8. CBFB-MYH11
7.2.9. BCR-ABL1 mbcr
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By Blood Cancer Type & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By End User:
8.2.1. National Reference Lab / Specialty Lab
8.2.2. University Hospital / Oncology Center
8.2.3. Community Hospital / IDN (Regional/National)
Chapter 9. Onco-hematology Molecular Testing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Type, 2023-2031
9.1.2. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.1.3. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.1.4. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By, End User 2023-2031
9.1.5. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.2.2. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.2.3. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker 2023-2031
9.2.4. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User,2023-2031
9.2.5. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.3.2. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.3.3. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.3.4. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-20
9.3.5. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.4.2. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.4.3. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.4.4. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.4.5. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, (US$ Million)
9.5.2. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.5.3. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.5.4. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.5.5. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Asusragen, Inc.
10.2.2. Bio-Rad Laboratories, Inc.
10.2.3. ICON plc
10.2.4. Illumina, Inc.
10.2.5. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
10.2.6. Invivoscribe, Inc.
10.2.7. QIAGEN N.V.
10.2.8. Thermo Fisher Scientific, Inc.
10.2.9. Cepheid
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Onco-hematology Molecular Testing Market Size is valued at USD 497.67 Mn in 2022 and is predicted to reach USD 1280.06 Mn by the year 2031
Onco-hematology Molecular Testing Market expected to grow at a 11.2 % CAGR during the forecast period for 2023-2031
Asuragen, Inc., Bio-Rad Laboratories, Inc., ICON plc, Illumina, Inc., Integrated DNA Technologies, Inc. (ArcherDx, Inc.), Invivoscribe, Inc., QIAGEN N